Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.

NCT00345696 is registered in ClinicalTrials.gov with Unidad Integral de Investigación en Oncología S.L. as lead sponsor.

NCT NCT00345696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00345696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of First Line Capecitabine Administered on Continuous Way Combined With Oxaliplatin and Bevacizumab Every Two Weeks in Metastatic Colorectal Cancer Patients.
Lead sponsor
Unidad Integral de Investigación en Oncología S.L.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2006
Completion date
January 31, 2011
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer